Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Celyad Sa ADR (NQ: CYAD )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, May 18, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 0.2000 (10)
Ask (Size) 0.5770 (1)
Prev. Close 0.4700
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 22,593,956
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
From Celyad Oncology SA
Via GlobeNewswire
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
From Celyad Oncology SA
Via GlobeNewswire

Performance

More News

Read More
Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights
From Celyad Oncology SA
Via GlobeNewswire
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
From Celyad Oncology SA
Via GlobeNewswire
Celyad Oncology announces receipt of Nasdaq delisting notice
From Celyad Oncology SA
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From Nasdaq
From Celyad Oncology SA
Via GlobeNewswire
Celyad Oncology reports first quarter 2023 financial results and recent business highlights
From Celyad Oncology SA
Via GlobeNewswire
Celyad Oncology announces receipt of Nasdaq initial notification on ADS bid price
From Celyad Oncology SA
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Celyad Oncology announces receipt of Nasdaq notice
From Celyad Oncology SA
Via GlobeNewswire
Celyad Oncology appoints Georges Rawadi as its new CEO
From Celyad Oncology SA
Via GlobeNewswire
Celyad Oncology reports full year 2022 financial results and recent business highlights
From Celyad Oncology SA
Via GlobeNewswire
Earnings Scheduled For March 23, 2023
Via Benzinga
Celyad Oncology to announce full year 2022 financial results and host conference call
From Celyad Oncology SA
Via GlobeNewswire
Why Titan Machinery Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why American Public Education Shares Are Trading Lower By Around 49%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Jounce Therapeutics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Celyad Oncology announces non-cash impairment
From Celyad Oncology SA
Via GlobeNewswire
REPEAT -- Celyad Oncology SA - Letter to Shareholders
From Celyad Oncology SA
Via GlobeNewswire
Celyad Oncology SA - Letter to Shareholders
From Celyad Oncology SA
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.